Wed.Jul 10, 2024

article thumbnail

Q&A: US Army Veteran Discusses His Experience with PTSD

Drug Topics

A former sergeant first class in the US Army discussed PTSD in an exclusive interview with Drug Topics.

503
503
article thumbnail

Pfizer research chief Dolsten to step down, with company at a crossroads

PharmaVoice

The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.

Vaccines 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

As Pharmacies Face Financial Distress, RxOwnership Uses Data to Increase Profits

Drug Topics

Chris Cella, RPh, vice president of RxOwnership at McKesson, talks about how independent pharmacies can help improve their bottom line.

article thumbnail

STAT+: FTC plans to sue PBMs over the high cost of insulin and other medicines

STAT

The U.S. Federal Trade Commission plans to sue the three largest pharmacy benefit managers over their negotiating tactics for various medicines, including insulin, that pushed patients toward higher-priced treatments, according to a source familiar with the matter. The step comes after the agency this week released a scathing report that found the three largest PBMs — Express Scripts, Caremark, and OptumRx — processed nearly 80% of the roughly 6.6 billion prescriptions that were di

Insurance 145
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Telehealth in OUD Treatment Offers Benefits, Challenges

Drug Topics

The study’s mixed findings on telehealth for opioid use disorder (OUD) treatment suggest a need for more individualized approaches to care.

236
236
article thumbnail

Researchers identify ‘molecular switch’ in lupus that could stymie harmful immune response

STAT

Lupus, in superhero terms, tells a devastating story. A loyal hero turns villain and works to destroy his own people. But new research asks the question: What if immune cells could be turned back into good guys, and actually help save tissue damaged by autoimmune disease?  Lupus is complicated because it wields the body’s own defenses against itself, generating a continuous immune misfire.

More Trending

article thumbnail

Free medical school tuition unlikely to have a major impact on the U.S. health care system

STAT

Most of Johns Hopkins University’s medical school students will have free tuition starting this fall, thanks to a $1 billion gift from Bloomberg Philanthropies, a longtime donor of the university, whose school of public health is named after Michael Bloomberg. The largesse is striking, but, even combined with other recent moves to relieve future doctors of crushing medical debt, the move may not reverberate to bring improvements to the broader health care system, experts say.

article thumbnail

FDA Approves Roflumilast Cream 0.15% for Atopic Dermatitis in Pediatric, Adult Patients

Drug Topics

The commercial product is expected to be available by the end of July.

FDA 216
article thumbnail

STAT+: Biopharma layoffs are leaving the industry’s scientists reeling — and in search of scarce opportunities

STAT

After getting laid off from Bristol Myers Squibb last December, Jennifer Ariazi is trying her best to be a Vulcan. Ariazi, a former BMS senior principal scientist, is a devout “Star Trek” fan. And she has made a personal mantra out of emulating the stoicism and tough-minded logic that define the fictional humanoid species. Layoffs happen.

134
134
article thumbnail

Cisplatin-Based Chemotherapy Linked to Hearing Loss in Cancer Survivors

Pharmacy Times

Extended treatment with high doses of cisplatin-based chemotherapy is associated with severe and progressive hearing loss.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

As the GLP-1 market booms, other healthcare companies are cashing in

PharmaVoice

As more Americans take obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and foster new health benefits.

130
130
article thumbnail

WSJ: FTC to sue PBMs over drug pricing tactics

Fierce Healthcare

Just one day after issuing a report blasting pharmacy benefit managers for their business practices and focus on consolidation and vertical integration, the Federal Trade Commission (FTC) is report | The FTC is planning legal action against pharmacy benefit managers for rebate tactics that may hinder consumers and independent pharmacies.

article thumbnail

Generative Artificial Intelligence Accurate in Screening Patients with Heart Failure for Clinical Trial Eligibility

Pharmacy Times

The RECTIFIER framework was able to screen patients with heart failure more accurately and with a cheaper cost than traditional screening methods.

124
124
article thumbnail

CMS floats 2.6% annual outpatient, ASC pay increase, new obstetrics Conditions of Participation

Fierce Healthcare

A proposed rule outlining the Centers for Medicare & Medicaid Services’ (CMS’) intended Medicare payment rates and policy updates for outpatient and ambulatory surgical centers (ASCs) in the co | The administration's CY 2025 OPPS and ASC Payment Systems proposed rule looks to improve obstetrical services, quality reporting and care access.

124
124
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Biden administration ignores calls to bolster hospital price transparency

STAT

The federal government will not modify regulations that dictate how hospitals publish their prices for consumers, ignoring pleas from patient advocates who have said hospitals still are not fully complying with the 3-year-old law. The Biden administration on Wednesday proposed an annual rule that sets payment rates for hospitals. This document is where the government has in the past rolled out changes to the so-called hospital price transparency rule, but the Biden administration did not address

Hospitals 123
article thumbnail

Scathing FTC Interim Report on PBMs Warrants Further Investigations, Immediate Action by Policymakers and Regulators

Pharmacy Times

Investigation confirms massive middlemen employ tactics like steering, inflated costs, low reimbursements, harmful contractual terms, etc, that hurt patients and independent pharmacies.

article thumbnail

Turning pilots into production: How to create, scale, and succeed with GenAI

pharmaphorum

Learn how to successfully transition pilots into production with GenAI in the pharmaceutical industry. Discover strategies to create, scale, and achieve success with this innovative technology.

121
121
article thumbnail

How Chevron's demise could impact employers, purchasers, health payers

Fierce Healthcare

Healthcare legal observers are still reacting to the Supreme Court’s recent decision to gut the Chevron doctrine, fundamentally altering the power federal agencies have to handle regulations as the | Industry leaders and legal observers are still coming to terms with the Supreme Court's landmark decision to overturn the Chevron doctrine.

120
120
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: VC Flagship Pioneering raises $3.6 billion in new funds

STAT

Flagship Pioneering, one of the largest firms investing in and creating new biotech companies, said Wednesday that it has raised $3.6 billion in new funding. The Cambridge, Mass.-based organization raised $2.6 billion for Flagship Pioneering Fund VIII, as well as $1 billion for what it described as side funds and sector-specific strategic partnerships.

119
119
article thumbnail

After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

pharmaphorum

After short but worrying delay, Arcutis gets FDA approval for flagship drug Zoryve in atopic dermatitis, which could further unlock sales growth

FDA 116
article thumbnail

Opinion: Expand community-based research to make clinical trials more diverse

STAT

Innovations in clinical trial designs and tools have the potential to unlock a new era of research that is more convenient for patients, more reflective of real-world treatment conditions, and more likely to enable participation of a diverse set of individuals. But a recent study reveals how far the U.S. is from realizing this potential: regions of the country with the worst social drivers of health are the least likely to host clinical trials.

115
115
article thumbnail

Flagship closes $3.6bn biotech fund, with a focus on AI

pharmaphorum

Flagship Pioneering raises $3.

110
110
article thumbnail

STAT+: Novo Nordisk’s weekly insulin rejected by FDA

STAT

The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes in a rare setback for the pharmaceutical giant. The agency has requests related to the manufacturing process and the use of the insulin specifically in type 1 diabetes patients, Novo said in a statement Wednesday. The company, which had submitted an application for the drug for both type 1 and type 2 patients, said it does not expect to be able to fulfill the requests this year.

FDA 114
article thumbnail

Study Finds Gender and Racial Disparities in Youth Psychiatric Inpatient Admissions

Pharmacy Times

The authors emphasize that these findings suggest a need for targeted resources that help reduce boarding and promote equitable access to care.

109
109
article thumbnail

STAT+: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more

STAT

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

article thumbnail

NICE recommends Ebglyss for atopic dermatitis patients

Pharmaceutical Technology

Almirall’s Ebglyss is predicted to hit blockbuster status in two years in the crowded atopic dermatitis market.

105
105
article thumbnail

STAT+: Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system

STAT

Fourth time’s the charm? Sanford Health is hoping so. Less than a year after scrapping its proposed merger with a Minnesota health system — its third failed deal since 2019 — South Dakota’s Sanford is attempting a new, multibillion-dollar mashup. The $7 billion, 45-hospital system plans to absorb Marshfield Clinic Health System, a $3 billion system of 11 hospitals across Wisconsin and northern Michigan.

article thumbnail

Is hydroxyzine addictive?

The Checkup by Singlecare

Hydroxyzine , the generic version of the brand name Vistaril, is a prescription drug and first-generation antihistamine. Hydroxyzine relieves various conditions, such as generalized anxiety disorder and nausea, and the symptoms of allergic skin reactions, such as itchiness and hives. It has also been used to decrease the severity of opioid withdrawal.

article thumbnail

The Current Landscape of Drug Shortages

Pharmaceutical Commerce

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth, founder and CEO, offers his thoughts surrounding the lack of supply.

105
105
article thumbnail

NICE backs monthly eczema drug from Almirall

pharmaphorum

NICE backs monthly eczema drug from Almirall Phil.

105
105
article thumbnail

The State of Patient Support Services in Today’s Landscape

Pharmaceutical Commerce

Why these programs require a hybrid approach that combines technology and human connection.

105
105
article thumbnail

uniQure rockets on Huntington’s gene therapy result

pharmaphorum

Shares in Dutch biotech uniQure shoot up after Huntington’s candidate AMT-130 slows disease progression by 80% two years after dosing.

105
105
article thumbnail

uniQure shares soar on Huntington’s data

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. It’s been a challenging time for workers in the biopharma industry. We’ve seen companies announce layoffs one after another, and people online talk about how it seems increasingly difficult to secure a new job.

FDA 104